The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-01. Anything still debated is marked as such rather than presented as settled.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Agriculture's role in developed countries has drastically changed in the last century due to many factors, including refrigeration. Statistics from the 2007 census gives information on the large concentration of agricultural sales coming from a small portion of the existing farms in the United States today. This is a partial result of the market created for the frozen meat trade by the first successful shipment of frozen sheep carcasses coming from New Zealand in the 1880s. As the market continued to grow, regulations on food processing and quality began to be enforced. Eventually, electricity was introduced into rural homes in the United States, which allowed refrigeration technology to continue to expand on the farm, increasing output per person. Today, refrigeration's use on the farm reduces humidity levels, avoids spoiling due to bacterial growth, and assists in preservation.
Noradrenergic and serotonergic nuclei in the ARAS are involved in the regulation of the REM sleep cycle and function as "REM-off" cells, with amphetamine's effect on norepinephrine and serotonin contributing to the suppression of REM sleep and a possible reduction of cataplexy at high doses. The American Academy of Sleep Medicine (AASM) 2021 clinical practice guideline conditionally recommends dextroamphetamine for the treatment of both type 1 and type 2 narcolepsy. Treatment with pharmaceutical amphetamines is generally less preferred relative to other stimulants (e.g., modafinil) and is considered a third-line treatment option. Medical reviews indicate that amphetamine is safe and effective for the treatment of narcolepsy. Amphetamine appears to be most effective at improving symptoms associated with hypersomnolence, with three reviews finding clinically significant reductions in daytime sleepiness in patients with narcolepsy. Additionally, these reviews suggest that amphetamine may dose-dependently improve cataplexy symptoms. However, the quality of evidence for these findings is low and is consequently reflected in the AASM's conditional recommendation for dextroamphetamine as a treatment option for narcolepsy.
==== Chromatography ==== High-performance liquid chromatography can be used to separate unconjugated and conjugated bilirubin, but the method has insufficient bias and precision to be a gold standard reference method, and it is too laborious and expensive for routine use.
Sources: en.wikipedia.org
=== 2009, Tucker & Tenorio === In 2009 John K. Tucker and Manuel J. Tenorio proposed a classification system for the cone shells and their allies (which resorb their inner walls during growth) was based upon a cladistical analysis of anatomical characters including the radular tooth, the morphology (i.e., shell characters), as well as an analysis of prior molecular phylogeny studies, all of which were used to construct phylogenetic trees. In their phylogeny, Tucker and Tenorio noted the close relationship of the cone species within the various clades, corresponding to their proposed families and genera; this also corresponded to the results of prior molecular studies by Puillandre et al. and others. This 2009 proposed classification system also outlined the taxonomy for the other clades of Conoidean gastropods (that do not resorb their inner walls), also based upon morphological, anatomical, and molecular studies, and removes the turrid snails (which are a distinct large and diverse group) from the cone snails, and creates a number of new families. Tucker and Tenorio's proposed classification system for the cone shells and their allies (and the other clades of Conoidean gastropods ) is shown in Tucker & Tenorio cone snail taxonomy 2009.
These decrees were described by historian Paul Ginsborg as “the only attempt made by leftist government officials to advance on the path of reform”. Gullo, who became “Minister of the Peasants”, achieved two important results: the southern peasants' became aware of the state's support and the laborers' realization that uniting in cooperatives brought them power. Thanks in part to cooperation with trade unions, especially Giuseppe Di Vittorio's Italian General Confederation of Labour, Gullo's reform efforts were extended with two other decrees. One modified the taxable labor rate. Trade unions were empowered to dictate the number of laborers on a landowner's farmland. The latter allowed trade unionists to manage the labor placements according to seniority. With these measures they prevented war and brought the union onto the side of the peasants. The Gullo decrees were opposed by the agrarians, using the organized underworld and by enlisting the support the more conservative of the Christian Democrats (CD), who were against the revolutionary government measures. Local Christian Democrats were often involved with the past regime. They succeeded in amending the decrees with provisions that made them unenforceable. Instead, agricultural cooperatives received uncultivated land from a special provincial commission, composed of the president of the Court of Appeals, one representative of the agrarians and one representative of the peasants.
== Controversy == On February 25, 2020, Consumer Reports published an article stating that GoodRx shared user data—specifically, pseudonymized advertising ID numbers that companies use to track the behavior of web users across websites, the names of the drugs that users browsed, and the pharmacies where users sought to fill prescriptions—with Google, Facebook, and around twenty other Internet-based companies. A few days later, GoodRx released a statement saying that it had made changes to prevent user search data on medical conditions and pharmaceuticals from being shared with Facebook. In March 2020, GoodRx stopped sending data about user prescriptions to Facebook. On February 1, 2023, the Federal Trade Commission fined GoodRx US$1.5 million for violations of the Breach Notification Rule and the Federal Trade Commission Act for allegedly failing to obtain specific, informed, and unambiguous consent from users before disclosing health-related information to Facebook and Google. In November 2024, independent pharmacies filed at least three class action lawsuits against GoodRx and major pharmacy benefit managers. The cases, brought by independent pharmacies in California, Michigan, Pennsylvania, and Rhode Island, allege that GoodRx and the PBMs collaborated to suppress reimbursements for generic prescription drugs. They allege that agreements using GoodRx's software suppressed reimbursements for generic drugs and violated the Sherman Antitrust Act. The suits claim the practices amount to price fixing which harms small pharmacies while benefiting PBMs and their affiliates.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.